Positions

Overview

  • CF researcher
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.American Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2017 Airway microbiota across age and disease spectrum in cystic fibrosis.European Respiratory Journal.  50. 2017
    2017 Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibroblasts.Bone Marrow Transplantation.  52:765-768. 2017
    2016 Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline.Annals of the American Thoracic Society.  13:2174-2183. 2016
    2016 Effect of Prenatal versus Postnatal Vitamin D Deficiency on Pulmonary Structure and Function in Mice.American Journal of Respiratory Cell and Molecular Biology.  56:383-392. 2016
    2016 Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening.Pediatric Pulmonology.  51:1168-1176. 2016
    2016 Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.Lancet Respiratory Medicine.  4:107-115. 2016
    2016 Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.Journal of Cystic Fibrosis.  15:67-73. 2016
    2015 Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes.Pediatric Pulmonology.  50:1244-1252. 2015
    2015 Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis.Pediatric Nephrology.  30:1879-1888. 2015
    2015 Acute Kidney Injury in Hospitalized Children With Cystic FibrosisJournal of Clinical Pediatric Nephrology.  2:5-5. 2015
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients.Clinical and Translational Science.  7:336-341. 2014
    2014 Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia.PLoS ONE.  9:e106842. 2014
    2013 Erratum: Myofibroblast differentiation and enhanced Tgf-B signaling in cystic fibrosis lung disease (PLoS ONE (2013) 8 (8))PLoS ONE.  8. 2013
    2013 Crohn's disease with pulmonary manifestations in children: 2 case reports and review of the literature.Journal of Crohn's and Colitis.  7:e85-e92. 2013
    2013 IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations.PLoS ONE.  8:e72398. 2013
    2013 Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease.PLoS ONE.  8:e70196. 2013
    2011 Plasma TGF-β₁ in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy.Pediatric Pulmonology.  46:688-695. 2011
    2010 Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas.Pediatric Pulmonology.  45:281-290. 2010
    2009 Transforming growth factor-beta(1) in bronchoalveolar lavage fluid from children with cystic fibrosis.Pediatric Pulmonology.  44:1057-1064. 2009
    2009 Experience of the school-aged child with tracheostomy.International Journal of Pediatric Otorhinolaryngology.  73:975-980. 2009
    2009 Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis.Pediatric Pulmonology.  44:503-511. 2009
    2006 Physiologic, bronchoscopic, and bronchoalveolar lavage fluid findings in young children with recurrent wheeze and cough.Pediatric Pulmonology.  41:709-719. 2006

    Research Overview

  • Cystic Fibrosis, Pediatric Lung Disease, TGF-beta signaling, Airway Remodeling, miRNA
  • Principal Investigator On

  • Overcoming Barriers to F508del CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami 2017 - 2019
  • MiR-145 Mediated TGF-Beta Pathobiology in CF  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • Private Grant  awarded by Gilead Sciences 2015 - 2017
  • Mechanisms of Pulmonary Fibrosis in CF Lung Disease  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Effect of Vitamin D Deficiency on Murine Lung Development and Function  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2013 - 2015
  • Myofibroblast Differentiation in Cystic Fibrosis  awarded by Cystic Fibrosis Foundation 2012 - 2015
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2013
  • Bronchoalveolar Lavage Fluid (BALF) Specimen Bank and Lower Airway Microbiome Analysis in Children and Adults With and Without Cystic Fibrosis (CF)  awarded by University of Colorado 2011 - 2013
  • Myofibroblast Proliferation in Cystic Fibrosis: A Novel Mechanism of Disease Modification  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2010 - 2012
  • Investigator On

  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2017 - 2018
  • Prevalence and Significance of Staphylococcus Aureus Small–Colony Variants  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2014 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation 2015 - 2016
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2015 - 2016
  • The Genetic Contribution to Drug Induced Renal lnjury:The Drug Induced Renal Injury Consortium (DIRECT)  awarded by INTERNATIONAL SAE CONSORTIOUM, LTD 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2015
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation 2014 - 2015
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation 2013 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013 - 2014
  • Private Grant  awarded by GRIFOLS, INC 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Pediatric Physician Training in Translational Research  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2008 - 2013
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013
  • Education And Training

  • Bachelor of Engineering in Materials Engineering, Rice University
  • Doctor of Medicine, Southwestern University
  • Johns Hopkins Hospital, Residency 2003
  • University of North Carolina Hospital, Postdoctoral Fellowship 2007
  • Full Name

  • William Harris
  • Blazerid

  • wtharris